[1] |
Sapisochín G, Fernández de Sevilla E, Echeverri J, et al. Liver transplantation for cholangiocarcinoma: current status and new insights[J]. World J Hepatol, 2015, 7(22):2396-2403.
|
[2] |
Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB, 2015, 17(8):669-680.
|
[3] |
McKay SC, Unger K, Pericleous S, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma[J]. HPB, 2011, 13(5):309-319.
|
[4] |
Li C, Shen W, Shen S, et al. Gene expression patterns combined with bioinformatics analysis identify genes associated with cholangiocarcinoma[J]. Comput Biol Chem, 2013(47):192-197.
|
[5] |
Xie D, Ren Z, Fan J, et al. Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy[J]. Am J Cancer Res, 2016, 6(3):577-586.
|
[6] |
Chen MH, Chiang KC, Cheng CT, et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma[J]. Oncotarget, 2014, 5(9):2372-2389.
|
[7] |
Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy[J]. World J Gastrointest Endosc, 2016, 8(3):128-142.
|
[8] |
Shen WF, Zhong W, Xu F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2009, 15(47):5976-5982.
|
[9] |
Zhang C, Liu LX, Dong ZR, et al. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications[J]. Tumour Biol, 2015, 36(3):1781-1789.
|
[10] |
Li YG, Zhang N. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma[J]. Dig Liver Dis, 2009, 41(8):605-608.
|
[11] |
Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery[J]. Cancer, 2013, 119(5):993-1003.
|
[12] |
Pandey A, Pandey P, Aliyari Ghasabeh M, et al. Unresectable intrahepatic cholangiocarcinoma: multiparametric MR imaging to predict patient survival[J]. Radiology, 2018, 288(1):109-117.
|
[13] |
Zhang Y, Shi SM, Yang H, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection[J]. J Cancer, 2019, 10(2):494-503.
|
[14] |
Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgical management of intrahepatic cholangiocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7):671-681.
|
[15] |
姚舜禹,荚卫东,葛勇胜,等.吲哚氰绿荧光示踪技术在肝癌解剖性肝切除中的应用 [J/CD].中华肝脏外科手术学电子杂志,2019,8(3):221-225.
|
[16] |
Aloia TA. Associating liver partition and portal vein ligation for staged hepatectomy: portal vein embolization should remain the gold standard[J]. JAMA Surg, 2015, 150(10): 927-928.
|
[17] |
Au KP, Chan SC, Chok KS, et al. Child-Pugh parameters and platelet count as an alternative to ICG test for assessing liver function for major hepatectomy[J]. HPB Surg, 2017:2948030.
|
[18] |
李鹏鹏,王志恒,黄罡,等.肝脏三维可视化技术在肝脏恶性肿瘤治疗规划中的应用研究[J].中华外科杂志,2017, 55(12):916-922.
|
[19] |
Joseph S, Connor S, Garden OJ. Staging laparoscopy for cholangiocarcinoma[J]. HPB, 2008, 10(2):116-119.
|
[20] |
马春阳,周益龙,李怀亮,等.混合现实术中导航技术联合三维可视化技术在复杂性肝癌切除术中的应用[J].中华医学杂志,2019, 99(4):279-283.
|
[21] |
Terasawa M, Ishizawa T, Mise Y, et al. Applications of fusion-fluorescence imaging using indocyanine green in laparoscopic hepatectomy[J]. Surg Endosc, 2017, 31(12):5111-5118.
|
[22] |
Gao Y, Li M, Song ZF, et al. Mechanism of dynamic near-infrared fluorescence cholangiography of extrahepatic bile ducts and applications in detecting bile duct injuries using indocyanine green in animal models[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(1):44-50.
|
[23] |
Baker MA, Maley WR, Needleman L, et al. Ex vivo resection of hepatic neoplasia and autotransplantation: a case report and review of the literature[J]. J Gastrointest Surg, 2015, 19(6): 1169-1176.
|
[24] |
Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(12): 4020-4028.
|
[25] |
Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. JAMA Surg, 2014, 149(6): 565-574.
|
[26] |
Ali SM, Clark CJ, Mounajjed T, et al. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience[J]. HPB, 2015, 17(3): 244-250.
|
[27] |
Kim DH, Choi DW, Choi SH, et al. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? a review of 17 years of experience in a tertiary institution[J]. Surgery, 2015, 157(4):666-675.
|
[28] |
Miyata T, Yamashita YI, Yamao T, et al. Clinical benefits of lymph node dissection in intrahepatic cholangiocarcinoma: a retrospective single-institution study[J]. Anticancer Res, 2017, 37(5):2673-2677.
|
[29] |
沙朦,Jeong SS,顾劲扬,等.肝内胆管癌行肝移植术的临床价值[J].中华器官移植杂志,2017, 38(4): 193-199.
|
[30] |
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2):213-220.
|
[31] |
Scheuermann U, Kaths JM, Heise M, et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience[J]. Eur J Surg Oncol, 2013, 39(6):593-600.
|
[32] |
Han K, Ko HK, Kim KW, et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. J Vasc Interv Radiol, 2015, 26(7):943-948.
|
[33] |
Yang GW, Zhao Q, Qian S, et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma[J]. Onco Targets Ther, 2015(8):1245-1250.
|
[34] |
Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients[J]. BMC Cancer, 2010(10):492.
|
[35] |
Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence[J]. Br J Radiol, 2017, 90(1076):20170061.
|
[36] |
Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):839-847.
|
[37] |
Miura JT, Johnston FM, Tsai S, et al. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(11):3716-3723.
|
[38] |
Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis[J]. Medicine, 2019, 98(5): e14013.
|
[39] |
奚松阳,房栋,霍介格.肝内胆管癌的分子靶向治疗进展[J].世界华人消化杂志,2018, 26(29):1707-1716.
|
[40] |
Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion[J]. J Surg Oncol, 2009, 100(6):500-504.
|
[41] |
Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2016, 23(8):2610-2617.
|